Health
Cognition Therapeutics Reaches Full Enrollment in Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies
- Type C Meeting with U.S. Food and Drug Administration (FDA) Scheduled for Second Half of January -PURCHASE, N.Y., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced that its expanded access program has reached full enrollment. Each of the individuals enrolled in the program are being treated with 100 mg of oral zervimesine daily for up to one y
About this update from Cognition Therapeutics, Inc.
[{"type":"image","alt":"Cognition Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Cognition Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":250,"height":70,"url":"https://media.zenfs.com/en/globenewswire.com/cc90d0cfc1ad93cdee05813266446f22"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/3G97CJjBroOGRUYevL.t.A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTExODtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/cc90d0cfc1ad93cdee05813266446f22","width":250,"height":70}},"lazy":false},{"type":"text","content":"- Type C Meeting with U.S. Food and Drug Administration (FDA) Scheduled for Second Half of January -","length":100,"tagName":"p"},{"type":"text","content":"PURCHASE, N.Y., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced that its expanded access program has reached full enrollment. Each of the individuals enrolled in the program are being treated with 100 mg of oral zervimesine daily for up to one year. The program was made possible through a generous donation from the family of a participant in the Phase 2 SHIMMER study of zervimesine (CT1812) in dementia with Lewy bodies (DLB).","length":584,"tagName":"p"},{"type":"text","content":"“We are grateful to the family who made it possible to provide expanded access to zervimesine for people who were in the Phase 2 DLB study,” stated Lisa Ricciardi, president and CEO of Cognition Therapeutics. “The efforts of our dedicated investigators and our clinical operations team made it possible to complete enrollment in only three months.”","length":348,"tagName":"p"},{"type":"text","content":"“The speed with which the program was enrolled is also a testament to the high level of interest among patients with DLB,” added Lawrence S. Honig, MD, PhD, professor of neurology at Columbia University Irving Medical Center and an investigator in the program. “The ability to provide our patients with a medication that they feel is making a meaningful difference in their lives is incredibly rewarding. I look forward to working with Cognition on the next phase of clinical development for zervimesine.”","length":505,"tagName":"p"},{"type":"text","content":"Having reached alignment with FDA on a registrational program f...